research use only
Cat.No.S2150
| Related Targets | EGFR VEGFR FGFR PDGFR c-Met Src MEK CSF-1R FLT3 c-Kit |
|---|---|
| Other HER2 Inhibitors | Sevabertinib (BAY 2927088) CP-724714 Sapitinib (AZD8931) Mubritinib (TAK 165) AC480 (BMS-599626) Tyrphostin AG 879 HER2-Inhibitor-1 Zongertinib (BI 1810631) TAS0728 IAM1363 |
|
In vitro |
DMSO
: 6 mg/mL
(10.77 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about Neratinib (HKI-272) solubility in DMSO or water
Read more about Neratinib (HKI-272) working concentrations for cell culture treatment
Neratinib (HKI-272) is a potent inhibitor of HER2 kinase (5.6 nmol/L), EGFR kinase (92 nM), MST1 (37.7 nM), EGFR (81 ± 9 nM), MAP4K4 (33.48 nM), MST2 (87.81 nM), HER2 (2–3 nM), HER4 (19 nM), BT474 (6.7 nM), EFM-192A (46.7 nM), UACC-812 (<5 nM), MDA-MB-361 (7.36 ± 2.65 nM), HCC1419 (3.94 ± 0.5 nM), HCC1569 (<5 nM), HCC1954 (325 nM), JIMT-1 (141.5 ± 9.61 nM), MDA-MB-453 (267.23 ± 22.52 nM), SKBR3 (10.2 nM), SUM-190 (10 ± 0.0 nM), SUM-225 (10 ± 0.0 nM), UACC-732 (650 ± 370 nM), UACC-893 (<5 nM), MCF7 (>3000 nM), T47D (890 nM), HCC1937 (750 nM), SUM-229PE (14 nM), MDA-MB-231 (496 ± 98 nM), MDA-MB-468 (36 nM), MCF10A HER2 WT (<2480 ± 50 nM), MCF10A G309A (<2470 ± 50 nM), MCF10A V777L (<21040 ± 570 nM), MCF10A D769H (<2980 ± 950 nM), MCF10A V842I (<2650 ± 210 nM), MCF10A del.755–759 (2.1 ± 0.2 nM), MCF10A L755S (15.6 ± 6 nM), MCF10A K75E (32 ± 8 nM), MCF10A L768S (<21050 ± 480 nM), MCF10A V773L (<2960 ± 380 nM), MCF10A R647K (<2650 ± 370 nM), MCF10A I655V (<2520 ± 420 nM), MCF10A K676R (<2385 ± 270 nM), MCF10A Q680R (<2550 ± 190 nM), MEK1, MEK2, P-gp, EGFR Cys-797, EGFR T790M, HER2 P780_Y781insGSP, HER2 K753E, HER2 L755S, HER2 D769Y, PIK3CA, PD-1, membrane-bound ATP transporter. Neratinib (HKI-272) exhibits the greatest inhibitory potency toward HER2 (IC50 = 2–3 nM).
| Information | Neratinib (HKI-272) is a potent, irreversible pan-HER and MST1 inhibitor. It affects EGFR/HER2, PI3K/AKT, and MAPK signaling by irreversibly binding to HER kinases and blocking downstream pathways, effectively inhibiting cancer cell proliferation and inducing apoptosis. |
|---|---|
|
Read more about Neratinib (HKI-272) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
| Molecular Weight | 557.04 | Formula | C30H29ClN6O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 698387-09-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | HKI-272 | Smiles | CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C | ||
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.